Business Standard

Thursday, December 19, 2024 | 05:38 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Covid-19: Indian sites await DCGI nod to restart Oxford vaccine trial

The Drug Controller General of India (DCGI) V G Somani will take a call after he receives data from the Data and Safety Monitoring Board (DSMB) in the UK as well as India

Photo: Bloomberg
Premium

The safety data is being analysed by the DSMB. Unless the DSMB gives its consent, the second shot of the vaccine will not be administered | Photo: Bloomberg

Sohini Das Mumbai
Even as late-stage trials for the UK arm of the Oxford-AstraZeneca Covid-19 vaccine have been suspended after a study participant suffered a ‘potentially unexplained illness’, India will wait until the country’s drug regulator gives the go-ahead to restart the trials, observed investigators here.

The Drug Controller General of India (DCGI) V G Somani will take a call after he receives data from the Data and Safety Monitoring Board (DSMB) in the UK as well as India.

According to sources close to the development, around 100 participants were administered the first shot of the vaccine (Covishield) here. The safety data is being analysed

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in